Puma Biotech (PBYI) Tops Q3 EPS by 113c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Puma Biotech (PBYI) PT Raised to $122 at Barclays on 3Q Report; 'Nerlynx Initial Launch Trend Encouraging, EU Decision in 1Q18'
November 10, 2017 1:10 PM ESTBarclays raised its price target on Puma Biotech (NASDAQ: PBYI) to $122.00 (from $103.00) while maintaining a Overweight rating, following the company's third quarter earnings report.
Analyst Gena Wang notes a positive outlook on the shares, as the company reported third quarter earnings per share and... More
Puma Biotechnology (PBYI) PT Raised to $142 at Credit Suisse, 'Early Trend Indicators Stronger Trajectory'
November 10, 2017 4:56 AM ESTCredit Suisse raised its price target on Puma Biotechnology (NASDAQ: PBYI) to $142.00 (from $136.00) while maintaining a Outperform rating.
Analyst Alethia Young models Nerlynx Q4 and 2018 sales at $28 million and $214 million respectively. The analyst believes the selloff following Thursday's report was due to high... More
Puma Biotechnology (PBYI) PT Raised to $164 at Citi, 'Buy The Dip'
November 10, 2017 4:14 AM ESTCiti raised its price target on Puma Biotechnology (NASDAQ: PBYI) to $164.00 (from $156.00) while maintaining a Buy rating.
Analyst Yigal Nochomovitz believes investors should buy the dip noting early metrics are looking very good even without the benefit of EAP and modest discontinuations. The... More
